Health Care • Biotechnology: Pharmaceutical Preparations
$5.72 ▼ -0.08
(-1.46%)
MKT CAP: $574.1M • VOL: 676.3K
52W L $2 52W H $8
STTK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.0M | $5.7M | $1.7M |
| YoY Revenue Growth % | -82.5% | +245.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$51.5M | -$80.6M | -$92.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$48.8M | -$75.4M | -$87.3M |
| EBITDA (Normalized) | -$51.5M | -$80.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$39.9M | -$60.5M | -$81.2M |
| Capital Expenditures (CapEx) | $71.0K | $59.0K | — |
| Free Cash Flow (FCF) | -$40.0M | -$60.6M | -$81.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $54.2M | $57.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $82.4M | $79.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR STTK.